跳至主要内容
临床试验/NCT02413359
NCT02413359
已完成
不适用

Research Study in Patients With COPD in High Risk Population in Japan: Proportion of Overlap Between COPD and Asthma, and the Relationship With COPD Exacerbation

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,016 人2015年5月
适应症COPD

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
COPD
发起方
AstraZeneca
入组人数
1016
试验地点
1
主要终点
Proportion of ACOS defined by The Global Initiative for Asthma (GINA) and The Global Initiative for Chronic Obstructive Lung Disease (GOLD) in patients with COPD receiving outpatient treatment and follow-up by physicians in Japan.
状态
已完成
最后更新
9年前

概览

简要总结

The patients with complications of COPD and asthma have features mixed with two diseases, COPD and asthma. Therefore, the outcomes are worsened if the patients with COPD have symptoms overlapped with asthma, however, no sufficient data exist in Japan for estimating the prevalence of ACOS in patients with COPD. The primary objective of this NIS is to clarify the proportion of ACOS defined by GINA and GOLD in patients with COPD. The main secondary objectives are To explore the features of history of COPD exacerbations, symptoms, eosinophilic inflammation and patient background in patients with ACOS, to clarify the history of COPD exacerbations in patients with COPD, to evaluate the degrees of eosinophilic inflammation of the respiratory tract in patients with COPD and to evaluate the symptoms in patients with COPD. This is a cross-sectional study targeting COPD patients receiving outpatient treatment and follow-up by physicians in Japan. FSI is scheduled as 2Q 2015 and DBL would be locked by 3Q 2015.

详细描述

Study Site(s), number of subjects planned Number of study sites planned for this research study (scheduled) 60 (undetermined) Number of subjects planned for this research study (scheduled) 1,100 patients

注册库
clinicaltrials.gov
开始日期
2015年5月
结束日期
2015年7月
最后更新
9年前
研究类型
Observational
性别
All

研究者

发起方
AstraZeneca
责任方
Sponsor

入排标准

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

Proportion of ACOS defined by The Global Initiative for Asthma (GINA) and The Global Initiative for Chronic Obstructive Lung Disease (GOLD) in patients with COPD receiving outpatient treatment and follow-up by physicians in Japan.

时间窗: up to 2 month

研究点 (1)

Loading locations...

相似试验